Trials / Completed
CompletedNCT03146416
Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers
A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Evinacumab in Healthy Japanese and Caucasian Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 96 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of the study is to compare the safety and tolerability of subcutaneous (SC) and intravenous (IV) doses of evinacumab in healthy Japanese and Caucasian subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Evinacumab | SC or IV administration of Evinacumab |
| DRUG | Placebo | Matching placebo |
Timeline
- Start date
- 2017-05-16
- Primary completion
- 2018-06-14
- Completion
- 2018-06-14
- First posted
- 2017-05-10
- Last updated
- 2018-06-25
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03146416. Inclusion in this directory is not an endorsement.